Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

March 16, 2026

Study Completion Date

March 16, 2027

Conditions

Lung Cancer

Interventions

DIAGNOSTIC_TEST

Blood Samples

"* Samples for ctDNA blood concentration and osimertinib plasma concentration~* Sample for genetic polymorphisms"

Trial Locations (4)

CH Saint Malo (Service de Pneumologie), St-Malo

Chu de Rennes (Service Pneumologie), Rennes

CH Bretagne Atlantique, Vannes

CH Bretagne Sud (Site du Scorff), Lorient

All Listed Sponsors

lead

Rennes University Hospital

OTHER